AUVELITY's Alzheimer's launch propels Axsome to $218M in Q2 revenue, a 46% surge; credit line expanded
AXSM has more than doubled off its 52-week low of $102.67.
Summary
Axsome Therapeutics posted Q2 2026 revenue of $218.4 million, a 46% increase driven by AUVELITY, and expanded its revolving credit facility by $20 million. Full financials and updated risk factors were disclosed.
Key Events · Earnings and Guidance · AXSM
-
Q2 Revenue Up 46% to $218.4M
Total revenues reached $218.4 million, driven by AUVELITY net sales of $180.3 million (up 51% YoY) following its April 2026 FDA approval for Alzheimer's disease agitation. SUNOSI contributed $33.8 million and SYMBRAVO $2.3 million.
-
Net Loss Widens on Launch Spending
Net loss was $51.3 million ($0.99/share) vs. $48.0 million a year ago, as SG&A expenses nearly doubled to $208.1 million to support the AUVELITY AADDAD launch and direct-to-consumer advertising.
-
Credit Facility Expanded by $20M
On June 26, 2026, the company amended its Blackstone loan agreement to increase the revolving credit facility from $70 million to $90 million and permitted indebtedness from $10 million to $20 million, providing additional liquidity.
-
Pipeline Progress: AXS-12 NDA Accepted
The FDA accepted the NDA for AXS-12 in narcolepsy cataplexy with a PDUFA date of May 1, 2027. Multiple Phase 3 trials are ongoing for solriamfetol in ADHD, binge eating disorder, and other indications.
Analysis · AXSM · Life Sciences
Second-quarter revenue jumped 46% year-over-year to $218.4 million, fueled by AUVELITY's new Alzheimer's agitation indication and robust base demand. The company also added $20 million to its revolving credit facility, bringing it to $90 million and enhancing financial flexibility. While the top line was pre-announced in an 8-K earlier today, the 10-Q delivers full financial statements, granular expense breakdowns, and fresh risk disclosures—including potential headwinds from pharmaceutical tariffs and most-favored-nation pricing policies. The net loss widened to $51.3 million from $48.0 million a year ago as SG&A spending nearly doubled to support the AUVELITY launch, but the revenue trajectory and pipeline momentum (AXS-12 NDA accepted, PDUFA May 2027) keep the investment thesis intact.
At the time of this filing, AXSM was trading at $220.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4B. The 52-week trading range was $102.67 to $260.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.